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Type 1 fimbriae are surface organelles of Escherichia coli which mediate D-mannose-sensitive binding to
different host surfaces. This binding is conferred by the minor fimbrial component FimH. Naturally occurring
variants of the FimH protein have been selected in nature for their ability to recognize specific receptor targets.
In particular, variants that bind strongly to terminally exposed monomannose residues have been associated
with a pathogenicity-adaptive phenotype that enhances E. coli colonization of extraintestinal locations such as
the urinary bladder. In this study we have used random mutagenesis to specifically identify nonselective
mutations in the FimH adhesin which modify its binding phenotype. Isogenic E. coli clones expressing FimH
variants were tested for their ability to bind yeast cells and model glycoproteins that contain oligosaccharide
moieties rich in either terminal monomannose, oligomannose, or nonmannose residues. Both the monoman-
nose- and the oligomannose-binding capacity of type 1 fimbriae could be altered by minor amino acid changes
in the FimH protein. The monomannose-binding phenotype was particularly sensitive to changes, with exten-
sive differences in binding being observed in comparison to wild-type FimH levels. Different structural
alterations were able to cause similar functional changes in FimH, suggesting a high degree of flexibility to
target recognition by this adhesin. Alteration of residue P49 of the mature FimH protein, which occurs within
the recently elucidated carbohydrate-binding pocket of FimH, completely abolished its function. Amino acid
changes that increased the binding capacity of FimH were located outside receptor-interacting residues,
indicating that functional changes relevant to pathogenicity are likely to be due to conformational changes of
the adhesin.
Bacterial adherence is normally critical for successful colo-
nization of a specific host tissue. The best-characterized group
of bacterial adhesins is constituted by fimbriae (11). Type 1, or
mannose-sensitive, fimbriae are found on the majority of Esch-
erichia coli strains and are widespread among other members
of the Enterobacteriaceae (15). Interaction between type 1 fim-
briae and receptor structures plays a key role in the coloniza-
tion of various host tissues by E. coli (1, 36). Also, in certain
strain backgrounds, type 1 fimbriae can be regarded as viru-
lence factors. Indeed, we and others have previously shown
that the expression of type 1 fimbriae in E. coli is linked to
urinary tract pathogenesis (5, 22). In mouse models, immuni-
zations with FimH and synthetic FimH peptides were shown to
prevent urogenital mucosal infection by E. coli (19, 35).
A typical type 1 fimbriated bacterium has 200 to 500 peri-
trichously arranged fimbriae on its surface. A single type 1
fimbria is a 7-nm-wide, approximately 1-mm-long rod-shaped
structure consisting of four different components that are
added to the base of the growing organelle (21). The bulk of
the structure is made up of about 1,000 copies of the major
subunit protein, FimA, polymerized into a right-handed helical
structure, but small quantities of the minor components, FimF,
FimG, and FimH, are also present (12, 18). The receptor-
recognizing element of type 1 fimbriae is the 30-kDa FimH
protein (17). The FimH protein is located at the tip of the
fimbria and is also interspersed along the fimbrial shaft (9, 17).
The FimF and FimG components are probably required for
integration of the FimH adhesin into the fimbriae (9, 12).
The components of the fimbrial organelle are encoded by
the chromosomally located fim gene cluster (14). In addition to
the structural components, this 9.5-kb DNA segment encodes
the fimbrial biosynthesis machinery as well as regulatory ele-
ments (Fig. 1). The fimbrial organelle components, FimA,
FimF, FimG, and FimH, are produced as precursors having an
N-terminal signal sequence. This sequence is subsequently re-
moved during export across the inner membrane. Thus, the
FimH protein is produced as a precursor of 300 amino acids
that is processed into a mature form of 279 amino acids (7, 12).
Further export from the periplasm and across the outer mem-
brane is dependent on a fimbria-specific export and assembly
system constituted by the FimC and FimD proteins (8, 10, 13).
By virtue of the FimH adhesin, type 1 fimbriae mediate
adhesion to a variety of mannosylated glycoproteins. The af-
finity of FimH variants toward mannose targets can vary due to
changes in the primary structure of this protein. In about 80%
of fecal E. coli isolates, the FimH adhesin is capable only of
binding to trimannose receptors. In contrast, the FimH ad-
hesins from approximately 70% of urinary tract isolates carry
minor mutations (compared to the fecal isolates) which en-
hance their ability to recognize monomannose receptors (33).
The mutant alleles confer a significantly higher tropism for the
uroepithelium and dramatically enhance the ability of E. coli to
colonize the mouse urinary tract (31). Some of the monoman-
nose-binding E. coli strains are also capable of recognizing
complex oligosaccharides with no terminally exposed mannose
residues (34). Additionally, a recent study has revealed that
FimH adhesins from meningitis-associated isolates of E. coli
confer binding to collagens and that this specificity change is
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due to a minor variation in the amino acid sequence of FimH
(25).
All FimH variants and their corresponding adhesive profiles
described hitherto have been characterized from fecal or clin-
ical strains selected to play a specific role in nature, namely,
interaction with mammalian host surfaces. Naturally occurring
fimH mutants, adapted to enhance the colonization of either
commensal intestinal or pathogenic extraintesintal niches,
might therefore have a relatively tight group of receptor affin-
ities that can be invoked only by highly specific structural
changes. With a view to probing the binding potential of the
FimH adhesin more extensively, we have created a random
mutant library based on the fimH gene from E. coli K-12 strain
PC31 and analyzed the functional impact of nonselective mu-
tations.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The strains and plasmids
used in this study are listed in Table 1. The E. coli K-12 strain HB101 (F9 lacI
kan) (2) was used as an intermediate host during plasmid construction work. All
subsequent phenotypic analyses were performed with the E. coli Dfim strain
S1918 (3). Cells were grown in Luria-Bertani (LB) broth (26) supplemented with
the appropriate antibiotics.
DNA techniques. Plasmid DNA was isolated using the QIAprep spin plasmid
kit (Qiagen). Restriction endonucleases were used as specified by the manufac-
turer (Biolabs or Pharmacia). The nucleotide sequences were determined on
both DNA strands by the dideoxynucleotide chain termination method (27).
Oligonucleotide primers were purchased from Gibco BRL. The primers ms7
(59-TACCTGTTTGCTGTACTGCTGATGG) and ms3 (TTGCCGTTAATCC
CAGACTCAC) were used.
Construction of the fimH mutant library. The 656-bp KpnI-HincII fragment of
the fimH gene was mutagenized by nucleotide misincorporation during subop-
timal PCR conditions. Four reactions were performed with three of the four
nucleotides present at 50 mM and the other present at 5 mM. Each reaction
mixture also contained 7 mM MgCl2 to increase the stability of noncomplemen-
tary base pairs and 0.5 mM MnCl2 to reduce the template specificity of the
polymerase. The error-prone PCR procedure was performed for 35 cycles with
two primers (ms7 and ms3) that flank the KpnI and HincII sites of the fimH gene.
The amplification products were combined, digested with KpnI and HincII,
purified after agarose gel electrophoresis, and religated into similarly cut plasmid
pMAS1 to construct a library of altered fimH genes. This ligation mix was used
to transform S1918(pPKL115) cells. The transformation mixture was made up to
10 ml, grown to approximately 10 times the initial library diversity, and stored as
aliquots at 280°C in 25% (vol/vol) glycerol.
Construction of defined fimH mutants. Gene changes encoding specific amino
acid substitutions were introduced into the wild-type fimH sequence by exchange
of restriction fragments from the mutant fimH genes. Unique restriction sites
within the fimH gene permitted the exchange of these fragments using standard
cloning procedures. Each construct was analyzed by restriction mapping and
subsequent nucleotide sequencing. Plasmids containing these chimeric fimH
genes were introduced into S1918(pPKL115) and tested in adhesion assays.
Agglutination of yeast cells. The capacity of bacteria to express a D-mannose-
binding phenotype was assayed by their ability to agglutinate yeast (Saccharo-
myces cerevisiae) cells on glass slides. Aliquots of washed bacterial suspensions at
an optical density at 550 nm (OD550) of 0.5 and 1% yeast cells were mixed, and
the time until agglutination occurred was measured. Furthermore, clones which
did not cause any agglutination under these conditions were also tested at
OD550 5 20 and/or low temperature but still did not react.
Yeast cell aggregation assay. Agglutination titers were determined by mixing
a suspension of E. coli cells (serially diluted from OD530 5 0.4) with yeast cells
(5 mg ml21 in phosphate-buffered saline [PBS]). Aggregation was monitored
visually, and the titer was recorded as the highest dilution giving a positive
aggregation result. For inhibition experiments, bacteria (OD530 5 0.4) and yeast
cells were mixed with serial dilutions of methyl-a-D-mannopyranoside solution
and the results were recorded as the highest dilution able to inhibit aggregation.
Adhesion assays. Adhesion assays were performed essentially as previously
described (30). In short, wells were coated with either yeast mannan, bovine
RNase B (Sigma), or human plasma fibronectin (obtained as described in ref-
erence 34) at a concentration of 10 mg ml21, washed three times with PBS, and
quenched with 0.2% bovine serum albumin (BSA) in PBS. Bacterial suspensions
containing identical cell numbers (107 CFU/100 ml) were added to the wells and
incubated at 37°C for 40 min. For determination of the mannose sensitivity of the
binding, this incubation was performed in the presence of 1% methyl-a-D-
mannopyranoside. The wells were washed with PBS, and the number of bound
bacteria was determined by a growth assay as previously described (33).
Bacterial interaction with anti-type 1 fimbriae and anti-FimH antiserum was
determined as follows. Polyclonal antiserum against purified type 1 fimbriae of E.
coli K-12 or a naturally occurring FimH truncate (gift of S. Hultgren, Washington
University, St. Louis, Mo.) was diluted 1:500 in 0.02 M sodium bicarbonate
(Sigma) and used to coat microtiter plates as described previously (30). Binding
of the bacteria to the immobilized antisera (in the presence of 2% methyl-a-D-
mannopyranoside) was determined as described above.
RESULTS
Construction of a fimH mutant library. The FimH adhesin
confers the ability to bind to various receptor targets by virtue
of an NH2-terminal receptor-binding domain (16, 19). To iden-
tify specific amino acids involved in receptor target recogni-
tion, we used the FimH expression vector pMAS1 (28). This
vector contains the fimH gene from E. coli K-12 strain PC31
(14) in pUC19 under transcriptional control of the lac pro-
moter. In addition, the plasmid contains unique KpnI and
HincII recognition sequences within the fimH gene, which
flank the region encoding the proposed FimH receptor-bind-
ing domain (Fig. 1). Random mutagenesis was performed on
the 656-bp KpnI-HincII fragment of fimH using a modified
PCR and Taq DNA polymerase. This polymerase possess an
intrinsic error frequency under optimal conditions of approx-
imately 1024 to 1025 error per bp (37). The error-prone PCR
amplification products were digested with KpnI and HincII and
religated into similarly cut plasmid pMAS1 to reconstruct a
library of altered fimH genes (Fig. 1). To permit expression of
the corresponding FimH variants as functional constituents of
type 1 fimbriae, the ligation mix was transformed into E. coli
strain S1918 (Dfim) containing an auxiliary plasmid, pPKL115,
which encodes the entire fim gene cluster except fimH. Using
this approach, we have specifically targeted our mutagenesis to
the region encompassing amino acids 8 to 225 of the mature
FimH protein.
Selection of clones with altered FimH phenotypes from the
mutant library. To determine the phenotypic mutant fre-
quency of the FimH library, 300 transformant colonies were
randomly picked and screened for their ability to agglutinate
yeast cells, the traditional assay for monitoring type 1 fimbria-
mediated binding. Of these, 44% were negative and 56% pos-
itive. Fifteen clones from the negative group and 50 clones
from the positive group were randomly picked for further
characterization of their binding profiles and tested for their
ability to bind model receptor-specific targets. As relevant tar-
get substrates, we used yeast mannan (Mn), bovine RNase B
(RB), fibronectin (Fn), and BSA. Mn represents the model
substratum for terminal monomannose-specific binding, RB
FIG. 1. Overview of the plasmids used to display FimH variants. Only rele-
vant nonvector regions are shown. (A) Plasmid pPKL115 contains the entire fim
gene cluster with a translational stop linker inserted into the fimH gene (trian-
gle). (B) The fimH expression vector pMAS1 is shown along with the strategy
employed to introduce random mutations into the receptor recognition domain
of the fimH gene. Primers ms3 and ms7 are described in Materials and Methods.











represents the model substratum for terminal oligomannose-
specific binding, and Fn represents the model substratum for
specific binding to oligosaccharides with no terminally exposed
mannose residues; BSA served as a control substratum for
monitoring of binding to protein substrates (30).
None of the clones that failed to agglutinate yeast cells in the
initial screening were able to recognize any of the model sub-
strates. Further studies revealed that all but one of these clones
showed only marginal reaction with antiserum against type 1
fimbriae and purified FimH; i.e., they were similar to the fimH-
null clone used as the negative control in these studies (data
not shown). Indeed, sequence analysis of the corresponding
fimH genes revealed that almost all of these clones had muta-
tions in the fimH gene that would result in a truncated protein
product. One of the nonagglutinating and nonbinding clones
exhibited a relatively strong reaction with the anti-FimH serum
and, possibly, expressed a nonfunctional FimH adhesin on the
surface.
In contrast to the agglutination-negative clones, all of the 50
agglutination-positive clones were able to bind at a detectable
level to at least one of the model substrates. These results
confirm the reliability of yeast agglutination as an efficient
screening assay for the identification of clones that express
functional FimH. The ability to bind model substrates was
assessed quantitatively to differentiate between clones with
unchanged phenotype, i.e. the wild-type-like adhesion, and
those with a variant FimH phenotype. The wild-type-like
clones were considered to be the ones that exhibited less than
50% deviation from the substrate-binding level of the control
strain expressing the original FimH adhesin from E. coli K-12
strain PC31 (i.e., strain S1918 containing pPKL115 and
pMAS1). According to this criterion, 37 clones (74%) had an
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant genotype Reference or source
E. coli strains
HB101 F9 laqIq 2
KB53 fimH gene from wild-type strain CI#4 33
KB59 fimH gene from wild-type strain CI#3 33
KB91 fimH gene from wild-type strain F-18 33
KB96 fimH gene from wild-type strain MJ2-2 33
S1918 F9 laqIq DfimB-H::kan 3
MS72 pMAS1 and pPKL115 in S1918 This study
MS205 pMAS63 and pPKL115 in S1918 This study
MS206 pMAS64 and pPKL115 in S1918 This study
MS208 pMAS66 and pPKL115 in S1918 This study
MS229 pMAS70 and pPKL115 in S1918 This study
MS233 pMAS72 and pPKL115 in S1918 This study
MS237 pMAS74 and pPKL115 in S1918 This study
MS239 pMAS75 and pPKL115 in S1918 This study
MS243 pMAS77 and pPKL115 in S1918 This study
MS272 pMAS88 and pPKL115 in S1918 This study
MS273 pMAS89 and pPKL115 in S1918 This study
MS276 pMAS92 and pPKL115 in S1918 This study
MS278 pMAS94 and pPKL115 in S1918 This study
MS279 pMAS95 and pPKL115 in S1918 This study
Plasmids
pPKL4 Wild-type fim gene cluster 14
pPKL115 All fim genes except fimH 23
pMAS1 fimH 28
pMAS63 Modified fimH gene (L125F, F142Y) This study
pMAS64 Modified fimH gene (G73E, L107F) This study
pMAS66 Modified fimH gene (Y175F, A204E) This study
pMAS70 Modified fimH gene (P490, P180Q) This study
pMAS72 Modified fimH gene (A188E) This study
pMAS74 Modified fimH gene (I52T, N152Y, G159V) This study
pMAS75 Modified fimH gene (A25P, R92P, D141N) This study
pMAS77 Modified fimH gene (L68F, S114R) This study
pMAS88 Modified fimH gene (A18T, F43S, R132Q, F215Y) This study
pMAS89 Modified fimH gene (R92H) This study
pMAS92 Modified fimH gene (S17G, K101E, Y175H, S216P) This study
pMAS94 Modified fimH gene (L183H, H201N) This study
pMAS95 Modified fimH gene (H201Q) This study
pPKL229 Modified fimH gene (A25P, R92P) This study
pPKL230 Modified fimH gene (D141N) This study
pPKL231 Modified fimH gene (A25P) This study
pPKL232 Modified fimH gene (R92P, D141N) This study
pTBK31 Modified fimH gene (G73E) This study
pTBK32 Modified fimH gene (L107F) This study
pTBK35 Modified fimH gene (P49Q) This study
pTBK36 Modified fimH gene (P180Q) This study
pTBK37 Modified fimH gene (L68F) This study
pTBK38 Modified fimH gene (S114R) This study











unchanged binding phenotype while the remaining 13 (26%)
clones demonstrated either a significantly lower or higher bind-
ing capability than the wild-type clone to at least one of the
model substrates tested.
Since this study focused on FimH adhesive phenotypes and
not on mutations which altered the fimbriation level, the vari-
ant clones were tested for their ability to react with a polyclonal
anti-type 1 fimbria antiserum and anti-FimH antiserum (data
not shown). Two of the clones demonstrated a significantly
lower ability to react with the anti-type 1 fimbrial serum com-
pared to the wild-type control and were not studied further.
The remaining 11 clones exhibited a wild-type-like interaction
with the fimbrial and FimH antisera, and we therefore con-
cluded that their variant adhesive phenotype resulted primarily
from alteration of the FimH receptor-binding domain. All of
these and two additional clones, randomly picked from the
wild-type-like receptor-binding group, were subjected to the
in-depth functional characterization and structural analysis
outlined below.
Detailed analysis of the functional variants of fimH. The
receptor-binding profiles of the variant, wild-type, and wild-
type-like clones are presented in Fig. 2A. Clones are listed
based on the ability to bind Mn, because the monomannose-
specific binding was previously shown to be the most variable
property among naturally occurring FimH isotypes (30). Inter-
estingly, all variant clones were able to bind the oligomannose-
specific substrate, RB. Although the binding range differed
10-fold, from 2.0 3 106 to 20.0 3 106 CFU/well, the average
difference from the wild-type level (8.0 3 106 CFU/well) was
only 55.0% 6 11.4%. The same strains exhibited more than a
150-fold range of Mn binding (from 0.05 3 106 to 8.7 3 106
CFU/well), with the average difference from the wild-type level
(1.7 3 106 CFU/well) being 161.4% 6 28.8% (r , 0.015). With
regard to the other model substrates tested, only two clones,
MS206 and MS243, were identified which, in contrast to the
wild type, had acquired the ability to bind to Fn at detectable
levels (Fig. 2A). No clones demonstrated an ability to bind the
protein test substrate BSA (data not shown). The results sug-
gest that the parental monomannose-binding phenotype, as-
sayed by binding to Mn, was the most sensitive to randomly
induced mutations, whereas the binding to the oligomannose
target, RB, seemed to be a property of the FimH adhesin that
is relatively resistant to structural alteration.
Based on the receptor-binding phenotypes depicted in Fig.
2A, the variant clones could be divided into four groups in
comparison to the wild-type phenotype. Group I clones are
distinguished by reduced binding characteristics compared to
the wild-type-like group (group II). Two other groups (III and
IV) exhibited significantly stronger binding to Mn than did the
wild-type control. However, while the group III clones showed
wild-type-like binding to RB, the two clones comprising group
IV exhibited significantly enhanced binding to both Mn and
RB in comparison to the wild-type control. In light of the
binding pattern exhibited by the clinical isolates (Fig. 2B), the
group III clones fall within the receptor-binding spectrum to-
ward Mn and RB observed in such strains selected in nature.
Furthermore, the binding patterns of the mutant strains of
groups I and III provide additional evidence for the notion that
monomannose-specific binding is a variable property of the
FimH adhesin while oligomannose binding is a conserved trait.
This would also suggest a certain level of structural and/or
functional autonomy between the two characteristics. The re-
maining group IV clones demonstrated binding phenotypes
with significantly increased affinity toward both Mn and RB
relative to the wild type. These types of alterations in FimH
receptor specificity are different from those seen in naturally
occurring FimH isotypes and possibly represent adhesive phe-
notypes that are selected against in nature.
Agglutination and inhibition. The classical assay for moni-
toring type 1 fimbria-mediated adhesion to eucaryotic cells is
agglutination of erythrocytes or yeast cells. Yeast cell aggluti-
nation is the most highly conserved binding property among
natural E. coli isolates and was used in this study to evaluate
the variation in receptor binding exhibited by the fimH mutant
clones examined in this study. The ability to bind yeast was
expressed as the highest dilution of bacterial suspension that
could confer agglutination. Bacterial adhesion to eucaryotic
cells under natural conditions is a function of the ability of the
adhesin to interact with the cognate receptor on the cell sur-
face but also depends on the sensitivity of the adhesin to
soluble inhibitory compounds that could bathe the cellular
target. Accordingly, we also determined the sensitivity of the
various clones to yeast cell agglutination in the presence of a
soluble inhibitor, methyl-a-D-mannopyranoside.
When the clones from the mutant library were tested for
their ability to agglutinate yeast cells, it became apparent that
the clones with wild-type-like receptor-binding profiles (i.e.,
clones from the wild-type-like group II and “flanking” clones
FIG. 2. Adhesion of E. coli expressing fimH variants selected from the mutant library (A) or naturally occurring fimH genes (B) to Mn, RB, and Fn. Clones are
grouped (I to IV) according to their FimH monomannose-binding phenotype. The level of significance between each of the groups was as follows: groups I and II, P ,
0.0005; groups II and III, P , 0.001; groups III and IV, P , 0.02. Additionally, a significant difference in RB binding was observed between groups III and IV (P ,
0.01). Values are means and standard errors (n 5 3).











from groups I and III) had relatively high agglutination titers
and ability to resist inhibition. However, this ability generally
dropped as the clones became more unlike the wild-type
clones. Notably, the “outer” group I and III clones, as well as
the two group IV clones, possessed a significantly lower capac-
ity to agglutinate yeast cells and/or to resist specific inhibition
(Fig. 3). These clones also differed most from the wild type in
Mn binding and RB binding, having significantly lower and
higher titers, respectively, than the wild type. Taken together,
the data indicate that mutants with adhesion profiles that are
significantly altered in monomannose and (especially) oligo-
mannose binding tend to have an inferior ability to adhere to
eucaryotic cells. Interestingly, increased sensitivity to soluble
inhibitors has been reported for natural variants that bind very
strongly to monomannose-like receptors, although it was not
accompanied by the decreased ability of the isolates to agglu-
tinate yeast cells (Fig. 3B).
Characterization of the amino acid substitutions introduced
by random mutagenesis. The nucleotide sequences of the fimH
genes of the 11 variant and 2 wild-type-like clones were deter-
mined; the corresponding amino acid sequences are presented
in Fig. 4. Overall, the PCR mutagenesis of the 656-bp region of
fimH resulted in one to four (an average of two) nonsynono-
mus mutations per clone. The changes were randomly distrib-
uted along the target sector, and the observed amino acid
changes were of diverse nature. It should be noted that the
nucleotide substitution rate gave an average of 3.5 substitu-
tions per clone; however, we have reported only the nucleotide
changes which alter the amino acid sequence of the protein.
Taken together, these data suggest that the PCR mutagenesis
technique we used was an adequate method for the introduc-
tion of a limited number of random structural alterations in the
FimH primary sequence.
The smallest number of changes was, not unexpectedly,
found in the wild-type-like group II, with the two clones MS279
and MS273 having single substitutions. In contrast to the wild-
type-like clones, the fimH genes of all the variant clones had
accrued nonsynonymous substitutions, varying from one
(MS233, group III) to four (MS272 and MS276, group I).
Within the groups, the mutations were distributed along the
FimH region without a notable phenotype-specific clustering.
Therefore, the substitution pattern observed in the mu-
tagenized FimH resembles the one defined previously for the
functional variations in FimH that occur under natural selec-
tion; i.e., mutations are limited in number and spread through-
out the protein.
In general, the substitutions observed in the variant clones
were of a diverse nature. The structural changes within FimH
in the MS229 and MS239 clones, which constitute the pheno-
typically most altered FimH variants, involved alteration or
introduction of proline residues. Proline often defines turning
regions within the peptide chain, and therefore such mutations
would be expected to cause dramatic changes in conformation
and function.
Amino acid changes that confer shifts in receptor specificity.
The majority of FimH variants identified in this study with
altered phenotypes were found to contain multiple amino acid
changes. To specifically define the functional impact of some of
these individual substitutions, we took advantage of unique
restriction sites to exchange segments with the wild-type fimH
gene.
The group III clones are particularly interesting since their
phenotype resembles those of naturally occurring FimH vari-
ants found in uropathogenic E. coli. Therefore, detailed anal-
yses of these clones could provide information on the mecha-
nism of natural selection of the FimH adhesin. Compared to
the parental FimH, the mutant FimH expressed by the group
III clone MS206 is characterized by a threefold increase in the
ability to bind Mn (the monomannose-specific substrate) and
in the acquired ability to bind human plasma Fn (the non-
mannose-specific substrate). Two mutations were defined in
the FimH-MS206 protein, G73E and L107F. When these
changes were introduced separately into the parental FimH
background, the G73E substitution was identified as the func-
tionally critical one (Fig. 5). Interestingly, a G73E mutation
has been identified as the functional change in a naturally
occurring FimH variant that has a similar adhesive profile to
MS206 (clone KB53, Fig. 2B) (34).
FimH from another group III clone, MS243, has two
changes, L68F and S114R. When these mutations were intro-
duced separately into the parental background, none of them
were individually capable of altering the wild-type phenotype
(Fig. 5). Therefore, both are required to increase the FimH
capability to bind monomannose receptor targets. Such a phe-
nomenon has not previously been seen among naturally occur-
ring FimH variants, where single mutations have been pin-
pointed to account for phenotypic changes.
The group I clone MS229 expresses a FimH variant with a
decreased ability to recognize any of the tested receptor sub-
strates, a phenotype not found among clinical isolates. We
hypothesized that the mutations introduced into this FimH
FIG. 3. (A) Agglutination titer of E. coli expressing fimH variants selected
from the mutant library. The titer is a measure of the highest dilution of bacterial
cells (from OD540 5 0.4) still able to give a positive aggregation result. (B)
Agglutination of E. coli expressing fimH variants selected from the mutant library
in the presence of the soluble inhibitor methyl-a-D-mannopyranoside. The dilu-
tion ratio is a measure of the highest dilution of methyl-a-D-mannopyranoside
(from the starting concentration of 1%) still able to inhibit aggregation. Values
are means and standard errors (n 5 3).











variant may therefore interfere with critical functional regions
of the adhesin. To investigate this, we introduced the muta-
tions separately in the FimH-K12 background. The P49Q sub-
stitution was found to be responsible for the abolition of FimH
function, while the P180Q mutation appeared to be function-
ally neutral. The P49 amino acid residue therefore appears to
be critical for receptor recognition by FimH.
We also examined the effect of the individual mutations in
the group IV clone MS239. This clone contains three amino
acid changes (A25P, R92P, and D141N) and possesses a phe-
notype of increased affinity to both Mn and RB. Dissection of
this clone to determine the effect of the individual changes
revealed that this phenotype was directly associated with the
A25P mutation (Fig. 5).
FIG. 4. Summary of mutations resulting in altered FimH phenotypes from the fimH mutant library and selected wild-type isolates. Asterisks indicate specific
mutations identified only in clinical isolates.
FIG. 5. Adhesion of E. coli expressing fimH genes with specific individual mutations to yeast Mn and RB. Chimeric fimH genes were constructed using unique
restriction sites to exchange fragments between mutant and wild-type genes. Values are means and standard errors (n 5 3).












Most of the type 1-fimbriated E. coli strains of human fecal
origin primarily recognize oligomannose-like receptors. In
contrast, FimH variants that enable E. coli to bind strongly to
monomannose-like receptors provide an adaptive advantage
for the bacterial colonization of the urinary tract. Indeed, the
monomannose-specific phenotype is dominant among uro-
pathogenic E. coli isolates while the oligomannose phenotype
is most common among fecal E. coli (31). A number of studies
have attempted to define the integral parts of the FimH adhe-
sin that contribute to receptor recognition. In-frame linker
insertion mutagenesis of fimH in positions corresponding to
amino acids 56 and 136 in the mature protein completely
abolished the ability of FimH to bind to D-mannose receptors
(29). Minor structural variations occurring naturally in the
FimH adhesin that can lead to physiologically important
changes in the pattern of receptor recognition have also been
found primarily within the N-terminal half of the FimH protein
(25, 34). Two studies involving fusions of sectors of FimH with
either MalE or FocH showed that a segment encompassing
amino acid residues 3 to 158 constituted a core region for
receptor recognition, with additional information residing in
the region from residues 159 to 201 (16, 35).
On this background, we created a mutant library by intro-
duction of mutations in the first two-thirds of the fimH gene
from the E. coli K-12 strain PC31 (whose sequence is identical
to that of the reference strain MG1655). Random mutagenesis
was performed on the region covering bp 85 to 740 (codons 8
to 225) of the 900-bp fimH gene by PCR mutagenesis, the same
sector previously identified to encode the receptor recognition
part of the adhesin. To construct a library of altered fimH
genes, the PCR amplification products were exchanged with
the wild-type gene copy in plasmid pMAS1 and introduced into
E. coli strain S1918 (Dfim) containing an auxiliary plasmid,
pPKL115, which carries the entire fim gene cluster except
fimH. This permitted expression of the corresponding FimH
variants as functional constituents of type 1 fimbriae and there-
fore allowed specific phenotypic analysis of the mutants. Using
this approach, we were able to analyze a wide spectrum of
FimH variants without alteration of the other fimbrial struc-
tural components, namely, FimA, FimF, and FimG.
The PCR mutagenesis resulted in 44% of the mutants being
nonfunctional, primarily due to the introduction of premature
stop codons in the fimH gene. The bacterial clones containing
truncated FimH proteins were unable to agglutinate yeast cells
or bind to any of the model receptor substrates. These results
concur with those of previous studies indicating that without
the C-terminal region, which is critical for the interaction of
FimH with the molecular chaperone FimC, the FimH protein
is highly unstable and is not incorporated into the fimbrial
organelle (9). These mutants were also characterized by a
severe decrease in the number of fimbriae visualized at the cell
surface, an observation consistent with the notion that FimH is
involved in the initiation of fimbrial organelle synthesis.
The majority (56%) of the clones were capable of causing
agglutination of yeast cells to various degrees. Fifty bacterial
clones selected randomly from this group were all able to bind
at least one of the model receptor substrates. Eleven of these
clones (22%) exhibited a FimH-specific receptor-binding phe-
notype that differed significantly from that of the parental K-12
FimH. Detailed analyses of the functionally altered mutants
revealed that the capacity of the FimH adhesin to recognize
monomannose-like receptor substrates is highly prone to
changes induced by the random mutagenesis while the oligo-
mannose recognition phenotype is a much more stable func-
tional property. This phenomenon corresponds to the pattern
observed in naturally selected FimH variants, which are char-
acterized by up to 15-fold variation in their ability to bind
monomannose but by only minor deviations in their oligo-
mannose-binding capacity (30).
Four (36%) of the functionally modified mutants (group III)
closely resembled the natural pathogenicity-adaptive pheno-
type of FimH. In comparison to the original wild-type K-12
FimH, these clones were able to bind monomannose at a
dramatically higher level, while their oligomannose-binding ca-
pability remained unchanged. In addition, two of these mu-
tants exhibited binding to human plasma Fn, a phenotype
highly specific to uropathogenic but not fecal E. coli isolates
(32). Therefore, the naturally occurring pathogenicity-adaptive
phenotype of the FimH adhesin could be induced at a rela-
tively high rate under nonselective conditions. The G73E sub-
stitution, which was found to be responsible for the strong
monomannose and Fn binding of the mutant clone MS206, has
also previously been identified in the uropathogenic strain
KB53 (33). However, the KB53 variant of fimH differs from the
K-12 variant in four other positions, V27A, N70S, S78N, and
H201D. Therefore, the G73E mutation imparts the same func-
tional effect on two structurally different FimH alleles, suggest-
ing that the same types of pathogenicity-adaptive mutations
might provide the selective functional changes in various clonal
variants of FimH across the E. coli species. The random mu-
tagenesis has also provided strong evidence that the pathoge-
nicity-adaptive phenotype of the FimH adhesin can be induced
via a cumulative effect of two functionally neutral substitutions.
Indeed, the L68F and S114R replacements do not affect the
K-12 FimH phenotype as separate changes, but their simulta-
neous presence in the mutant clone MS243 dramatically in-
creases the monomannose-binding capability. This would sug-
gest that certain allelic variants of FimH that bear one of the
neutral replacements would be more primed than other FimH
alleles to evolve into the pathogenicity-adaptive variant.
The FimH mutant clone MS229 from group I and the two
group IV clones demonstrate the most profound functional
alterations of FimH since they affect its highly conserved oli-
gomannose-binding property. Such types of functional alter-
ations have not been previously observed among commensal or
pathogenic isolates of E. coli. It is possible that the altered
oligomannose-binding phenotype of the FimH protein is phys-
iologically detrimental to E. coli in its natural environment.
Indeed, the most distinctive clones from group I (MS229) and
group IV (MS239) demonstrate a significantly decreased abil-
ity to bind to model target cells (yeast) and to overcome in-
terference with adhesion by soluble inhibitors. It is possible,
however, that such mutants do occur and are selectively ad-
vantageous under some yet unidentified natural conditions.
The group I mutant clone MS229 contains the amino acid
replacement P49Q that is responsible for abolishing the oligo-
mannose-binding capability of the FimH adhesin, while the
group IV clone MS239 demonstrates an increased oligoman-
nose-binding capability due to the A25P substitution in its
FimH. Interestingly, the P49Q substitution occurs in the
YPETITD54 amino acid stretch that is homologous to the
YPNTD16 region of the mannose-specific jack bean lectin,
concanavalin A (ConA). Based on studies that have resolved
the three-dimensional structure of the ConA lectin cocrystal-
lized with trimannoside compounds, the YPNTD16 region of
ConA is built by the residues that form a pocket capable of
accommodating a complex oligomannose receptor structure
(20). This would suggest that the P49 residue of FimH is part
of its oligomannose-combining site. Further evidence that the
P49 residue could be within the FimH receptor-binding site











was provided by the X-ray structure of the FimH adhesin (in
complex with the molecular chaperone, FimC) that was re-
ported during the preparation of this paper (4). According to
the X-ray study, the P49 residue is located within a pocket of
the FimH protein that binds to a molecule of cyclohexylbu-
tanoyl-N-hydroxyethyl-D-glucamide (C-HEGA). C-HEGA is
not a known inhibitor of FimH-mediated mannose binding but
was used as the cocrystallizing compound to obtain FimH-
FimC crystals of the necessary quality. The defined carbohy-
drate-binding pocket was shown to accommodate only the glu-
camide moiety of C-HEGA, a relatively small molecule.
Therefore, it is difficult to speculate how FimH interacts with
larger receptor compounds like trimannose or with other
known oligosaccharide inhibitors that exhibit 10- to 30-fold-
higher binding affinity to FimH than does monomannose (6).
According to the reported structure of the FimH-FimC com-
plex, the FimH protein is folded into two domains, an NH2-
terminal lectin domain (residues 1 to 156) and a COOH-
terminal pilin domain (residues 160 to 279). An important
pattern emerges from the analysis of the distribution of func-
tional amino acid substitutions that have been identified in this
and previous studies (Fig. 6). The decreased binding capability
of FimH (i.e., group I clones) is caused by mutations that occur
either within or near the carbohydrate-interacting residues that
form the FimH-binding pocket at the tip of the jelly-roll-
shaped lectin domain. Conversely, the changes resulting in an
increased monomannose-binding capability of FimH (i.e.,
group III and IV clones) do not interact directly with the
mannose receptor site. Instead, these mutations occur in the
“bottom” part of the lectin domain. Such a mirror-image dis-
tribution of the monomannose-binding enhancing substitu-
tions is highly nonrandom (P , 0.0001) and could not be
recognized without knowledge of the FimH crystal structure.
Therefore, the enhanced monomannose binding of the mu-
tants is most probably conformational, possibly due to alter-
ation of the conformational stability of the protein loops that
carry the receptor-interacting residues. This type of phenom-
enon has also been observed in serine proteases, where sub-
stitution of such rigidity-providing residues has been shown to
result not in the abolition but in the broadening of substrate
specificity (24). This specificity-broadening functional pattern
is characteristic of the monomannose- and fibronectin-binding
FimH variants.
It is very likely that a thorough understanding of the struc-
tural and functional basis of the natural adaptability of the E.
coli FimH adhesin will require cocrystallization of different
FimH variants with various types of receptor molecules and,
possibly, with other associated proteins within the fimbrial
organelle structure. In this context, the FimH variants identi-
fied in this study constitute a well-defined group of variants
based on the K-12 FimH allele. Studies on the adaptability of
the E. coli FimH protein may serve as a model paradigm for
the analysis of other bacterial adhesins or, basically, of any
microbial traits that can be functionally modified by naturally
occurring mutations to result in enhanced virulence.
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